Please Wait
Applying Filters...
menu
    • menu
    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    DTP Vaccine

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 9Boostrix

    02 4Infanrix, Pediarix

    03 5Infanrix/Pediarix

    04 8Tetrabik

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Infanrix/Pediarix

    Diphtheria, Tetanus Acellular, and Pertussis

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Infanrix/Pediarix

    United Kingdom
    arrow
    BIO Partnering at JPM
    Not Confirmed

    GlaxoSmithKline

    Diphtheria, Tetanus Acellular, and Pertussis

    Main Therapeutic Indication : Vaccine

    Currency : USD

    2020 Revenue in Millions : 764

    2019 Revenue in Millions : 1,016

    Growth (%) : -25

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Boostrix

    Diphtheria, Tetanus Acellular, and Pertussis

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Boostrix

    United Kingdom
    arrow
    BIO Partnering at JPM
    Not Confirmed

    GlaxoSmithKline

    Diphtheria, Tetanus Acellular, and Pertussis

    Main Therapeutic Indication : Vaccine

    Currency : USD

    2020 Revenue in Millions : 660

    2019 Revenue in Millions : 810

    Growth (%) : -18

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Tetrabik

    Diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain)

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Tetrabik

    Japan
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Mitsubishi Tanabe

    Diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain)

    Main Therapeutic Indication : Vaccine

    Currency : USD

    2020 Revenue in Millions : 98

    2019 Revenue in Millions : 84

    Growth (%) : 16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Tetrabik

    Diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain)

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Tetrabik

    Japan
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Mitsubishi Tanabe

    Diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain)

    Main Therapeutic Indication : Vaccine

    Currency : USD

    2021 Revenue in Millions : 90

    2020 Revenue in Millions : 96

    Growth (%) : 1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Boostrix

    Diphtheria, Tetanus Acellular, and Pertussis

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Boostrix

    United Kingdom
    arrow
    BIO Partnering at JPM
    Not Confirmed

    GlaxoSmithKline

    Diphtheria, Tetanus Acellular, and Pertussis

    Main Therapeutic Indication : Vaccine

    Currency : USD

    2021 Revenue in Millions : 705

    2020 Revenue in Millions : 652

    Growth (%) : 9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Infanrix/Pediarix

    Diphtheria, Tetanus Acellular, and Pertussis

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Infanrix/Pediarix

    United Kingdom
    arrow
    BIO Partnering at JPM
    Not Confirmed

    GlaxoSmithKline

    Diphtheria, Tetanus Acellular, and Pertussis

    Main Therapeutic Indication : Vaccine

    Currency : USD

    2021 Revenue in Millions : 735

    2020 Revenue in Millions : 755

    Growth (%) : -1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Tetrabik

    Diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain)

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Tetrabik

    Japan
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Mitsubishi Tanabe

    Diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain)

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2022 Revenue in Millions : 70

    2021 Revenue in Millions : 88

    Growth (%) : -20

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Infanrix, Pediarix

    Diphtheria, Tetanus Acellular, and Pertussis

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Infanrix, Pediarix

    United Kingdom
    arrow
    BIO Partnering at JPM
    Not Confirmed

    GSK

    Diphtheria, Tetanus Acellular, and Pertussis

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2022 Revenue in Millions : 732

    2021 Revenue in Millions : 735

    Growth (%) : 0

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Boostrix

    Diphtheria, Tetanus Acellular, and Pertussis

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Boostrix

    United Kingdom
    arrow
    BIO Partnering at JPM
    Not Confirmed

    GSK

    Diphtheria, Tetanus Acellular, and Pertussis

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2022 Revenue in Millions : 732

    2021 Revenue in Millions : 705

    Growth (%) : 4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Boostrix

    DTP Vaccine

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Boostrix

    United Kingdom
    arrow
    BIO Partnering at JPM
    Not Confirmed

    GSK

    DTP Vaccine

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2023 Revenue in Millions : 663

    2022 Revenue in Millions : 732

    Growth (%) : 3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.